Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lynt Johnson

Transplant Surgery Washington, DC Medical Doctor

NPI 1114926565 CMS profile 1220760

2131 K St Nw Ste 800, Washington, DC 20037

Open in the dashboard

General payments

$153,777

253 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lynt Johnson of Washington, DC is reported in the CMS Open Payments database as having received $153,777 across 253 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Transplant Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $127,763 109
2024 General $10,879 62
2023 General $6,867 24
2022 General $679 13
2021 General $322 6
2020 General $2,862 10
2019 General $4,405 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lynt Johnson
  • Transplant Surgery median
  • Middle half of Transplant Surgery
  • National median

In program year 2025, general payments to Lynt Johnson were reported at $127,763. Among 555 Transplant Surgery profiles paid that year, the median was $421 and the middle half received between $116 and $2,169.

Show as a table
Year Lynt Johnson Transplant Surgery median Middle half National median
2019 $4,405 $203 $77–$1,249 $163
2020 $2,862 $149 $52–$1,366 $114
2021 $322 $168 $73–$2,008 $132
2022 $679 $213 $94–$1,464 $149
2023 $6,867 $262 $93–$1,458 $160
2024 $10,879 $354 $126–$2,252 $164
2025 $127,763 $421 $116–$2,169 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Dilon Technologies, Inc. $129,340 85 payments
  2. Intuitive Surgical, Inc. $8,820 29 payments
  3. Boston Scientific Corporation $3,884 21 payments
  4. Transenterix, Inc. $3,481 18 payments
  5. Veloxis Pharmaceuticals, Inc. $2,975 22 payments
  6. TransMedics, Inc. $1,663 2 payments
  7. Covidien LP $798 5 payments
  8. Medtronic, Inc. $328 5 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $270 12 payments
  10. Madrigal Pharmaceuticals $270 2 payments
  11. Other $1,948 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $108,785 31 payments
  2. Travel and Lodging $27,110 50 payments
  3. Food and Beverage $11,507 159 payments
  4. Education $4,067 11 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,300 1 payment
  6. Gift $9 1 payment
Products named General payments · program years 2019–2025
  1. HEMOBLAST BELLOWS $129,340 85 payments
  2. Da Vinci Surgical System $4,820 26 payments
  3. DAVINCI XI $4,000 3 payments
  4. TheraSphere Y90 Glass Microspheres 10 GBq $3,884 21 payments
  5. Senhance Surgical Robotics System $3,481 18 payments
  6. Envarsus $2,776 14 payments
  7. ORGAN CARE SYSTEM $1,663 2 payments
  8. Emprint $741 4 payments
  9. XIFAXAN $299 13 payments
  10. REZDIFFRA $270 2 payments
  11. Other $2,536 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$89,172

Medicare's payments for the services billed

Medicare patients

80

Average age 72

Services billed

164

45 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 49%
Ischemic heart disease 40%
Chronic kidney disease 39%
Depression 29%
Cancer 23%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $160
$160 — —
Fetroja
  • Shionogi Inc $53
$53 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $30
$30 — —
OCALIVA
  • INTERCEPT PHARMACEUTICALS, INC. $20
$20 — —
Rezzayo
  • Melinta Therapeutics, Inc. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

253 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Transplant Surgery in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record